Ascension Wisconsin recently honored Racine paramedics and the Ascension All Saints Hospital Emergency Department for their ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

FDA approval was based on the AcT noninferiority trial that found tenecteplase (at 0.25 mg/kg) to be at least on par with alteplase for safety and efficacy in acute ischemic stroke in Canadians ...

The US Food and Drug Administration has approved Tenecteplase as first FDA-approved stroke medication in nearly three decades ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified ...

The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

Ascension All Saints Hospital recognized its medical staff and paramedics from the Racine Fire Department for their quick ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...